Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lymphoma Cancer

Brielle Benyon
The Food and Drug Administration (FDA) expedited the approval of Adcetris (brentuximab vedotin) in combination with chemotherapy for certain patients with peripheral T-cell lymphoma (PTCL).
Brielle Urciuoli
The Food and Drug Administration (FDA) granted a breakthrough therapy designation to Adcetris (brentuximab vedotin) for the frontline treatment of certain lymphoma subtypes, according to Seattle Genetics, the manufacturer of the antibody-drug conjugate.
Katie Kosko
Preventing febrile neutropenia is crucial because the body’s white blood cells help to fight infection.
Kristie L. Kahl
Lawrence D. Kaplan, M.D., discusses recent updates and next steps to be taken in Hodgkin, mantle cell and follicular lymphoma.
Kristie L. Kahl
Entospletinib monotherapy yielded limited activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Kristie L. Kahl
The Food and Drug Administration (FDA) granted fast track designation to selinexor for the treatment of patients with diffuse large B-cell lymphoma (DLBCL), according to Karyopharm Therapeutics, the drug’s manufacturer.
Beth Fand Incollingo
People with slow-growing B-cell lymphomas and no symptoms are often prescribed a watch-and-wait approach, which involves monitoring until the disease grows and warrants treatment.
Katie Kosko
Treating older patients who have Hodgkin lymphoma with Adcetris (brentuximab vedotin) before and after chemotherapy showed improved remission and survival rates, according to phase 2 study findings.
Kristie L. Kahl
The Food and Drug Administration has granted a priority review to the supplemental new drug application for Jakafi (ruxolitinib) to treat patients with acute graft-versus-host-disease (GVHD) who have had an inadequate response to corticosteroids.
Brielle Urciuoli
When Paul Isenberg’s wife, Nicole, was diagnosed with stage 4 Hodgkin lymphoma shortly after the birth of their child, Gabrielle, the couple realized two things: how blessed they were and that some people going through cancer have nobody to turn to.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other